Translational biomarkers can play a critical role in helping you quickly assess biomarker feasibility to better understand how it can be utilized in a clinical environment. When it comes to analytical characterization, one size doesn’t fit all. You need a flexible approach that considers your phase of development and desired outcomes to provide the best support for the intended use of your data.
Exploratory biomarkers, while not guided by specific regulations, still utilize robust quality principles, expertise and process to deliver high-quality and reliable data. A trusted partner who has familiarity with CAP/ CLIA and GxP environments can streamline your transition and retain critical insights about your assay and goals.